High Relaxivity GBCA Injection Step 1 of 7 14% Untitled Document Please Note: This program has been approved for Physician CME Credit Program Description / Statement of Need: This live symposium titled “High Relaxivity GBCA Injection” will discuss recent developments utilizing the most recently FDA approved gadolinium-based contrast agent (GBCA). Healthcare professionals are recognizing the clinical impact of contrast agent selection and understanding the physics of relaxivity in MRI for increased patient care. The purpose of this live symposium is to provide physicians and other healthcare professionals with current clinical data to make informed decisions in their clinical settings. Target Audience: The content of this CME Symposium is intended for healthcare professionals including Radiologists and Other Physicians, Radiologic and Imaging Nurses, Facility Managers, Researchers, Administrators and other healthcare professionals. Accreditation and CME Credit Statements: This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the sponsorship of Northwest Imaging Forums. NWIF is accredited by the ACCME to provide CME for physicians. NWIF designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits ™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Nurses may claim credit for activities approved for AMA PRA Category 1 Credits ™ in most states, for up to 50% of the nursing requirement for recertification. This course is designated for 1.0 AMA PRA Category 1 Credits ™. Faculty and Planner Disclosures: As an accredited provider of continuing medical education, it is the policy of Northwest Imaging Forums, Inc. (NWIF) to ensure balance, independence, objectivity, and scientific rigor in all of its activities. In accordance with this policy, faculty and planners must disclose any financial relationships with commercial interests germane to program content. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of NWIF to ensure that the COI is resolved in order to ensure the integrity of the CME activity. The planner has nothing to disclose. Select an Event*High Relaxivity GBCA InjectionPlease choose the applicable accreditation* Physician CME Full Name* First Last CredentialsMDMD, PhDDOPASpecialty* Facility* * Street Address Address Line 2 City State / Province / Region ZIP / Postal Code AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Phone*Email* I certify that I attended the above referenced conference claiming XX Hours of credit (maximum for this activity is 1.0 hour (credit).*.25.50.751.0I certify that I have completed this CME activity as designedSignature*Date* MM slash DD slash YYYY Evaluation:Please evaluate the effectiveness of this CME activity on a scale of 1 to 5, with 1 being the LOWEST, and 5 being the HIGHEST by selecting your choice.1. Overall quality of this CME activity 1 Lowest 2 3 4 5 Highest 2. Content 1 Lowest 2 3 4 5 Highest 3. Format 1 Lowest 2 3 4 5 Highest 4. Speaker EvaluationDiana Kaya, M.D.* 1 Lowest 2 3 4 5 Highest 5. Achievement of Educational ObjectivesA. Review the latest approved FDA GBCA.* 1 Lowest 2 3 4 5 Highest B. Discuss the clinical impact of contrast agent selection.* 1 Lowest 2 3 4 5 Highest C. Develop efficient MRI protocols to maximize diagnostic imaging and patient care.* 1 Lowest 2 3 4 5 Highest D. Explore new uses and smaller doses for recently approved high relaxivity GBCAs* 1 Lowest 2 3 4 5 Highest 6. This CME activity provided a balanced, scientifically rigorous presentation of therapeutic options related to the topic, without commercial bias. 1 Lowest 2 3 4 5 Highest Comments 7. Please describe how this CME activity will change your practice and/or the strategies you plan to implement in your practice.8. Please comment on the impact (if any) that this CME activity might have on the clinical care you administer.9. Additional comments and/or suggested topics for future CME activities?NameThis field is for validation purposes and should be left unchanged.
